148 related articles for article (PubMed ID: 18793550)
21. Experience with starting tacrolimus postoperatively after transsternal extended thymectomy in patients with myasthenia gravis.
Ponseti JM; Azem J; Fort JM; López-Cano M; Vilallonga R; Gamez J; Armengol M
Curr Med Res Opin; 2006 May; 22(5):885-95. PubMed ID: 16709310
[TBL] [Abstract][Full Text] [Related]
22. Long-term efficacy and side effects of low-dose tacrolimus for the treatment of Myasthenia Gravis.
Tao X; Wang W; Jing F; Wang Z; Chen Y; Wei D; Huang X
Neurol Sci; 2017 Feb; 38(2):325-330. PubMed ID: 27873026
[TBL] [Abstract][Full Text] [Related]
23. Long-term treatment of generalised myasthenia gravis with FK506 (tacrolimus).
Konishi T; Yoshiyama Y; Takamori M; Saida T
J Neurol Neurosurg Psychiatry; 2005 Mar; 76(3):448-50. PubMed ID: 15716549
[TBL] [Abstract][Full Text] [Related]
24. Successful treatment of myasthenia gravis with tacrolimus.
Evoli A; Di Schino C; Marsili F; Punzi C
Muscle Nerve; 2002 Jan; 25(1):111-4. PubMed ID: 11754194
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of tacrolimus in treatment of polymyositis associated with myasthenia gravis.
Shimojima Y; Gono T; Yamamoto K; Hoshi K; Matsuda M; Yoshida K; Ikeda S
Clin Rheumatol; 2004 Jun; 23(3):262-5. PubMed ID: 15168159
[TBL] [Abstract][Full Text] [Related]
26. [Glomerulonephritis and thymoma: a case report and review of the literature].
Zbiti N; Ouadnouni Y; Arrayhani M; Houssaini TS; Rhou H; Benamar L; Ouzeddoun N; Zaitouni F; Alhamany Z; Benosman A; Bayahia R
Rev Pneumol Clin; 2009 Oct; 65(5):322-4. PubMed ID: 19878810
[TBL] [Abstract][Full Text] [Related]
27. Myasthenia Gravis Complicated with Peripheral T-cell Lymphoma, Not Otherwise Specified (PTCL-NOS), Following Thymectomy and Longstanding Tacrolimus Therapy.
Ohara M; Ozaki K; Ohkubo T; Yamada A; Numasawa Y; Tanaka K; Tomii S; Ishibashi S; Sanjo N; Yokota T
Intern Med; 2018 Feb; 57(4):601-604. PubMed ID: 29269644
[TBL] [Abstract][Full Text] [Related]
28. Tacrolimus hydrate (FK506): therapeutic effects and selection of responders in the treatment of myasthenia gravis.
Wakata N; Saito T; Tanaka S; Hirano T; Oka K
Clin Neurol Neurosurg; 2003 Dec; 106(1):5-8. PubMed ID: 14643908
[TBL] [Abstract][Full Text] [Related]
29. Adequate tacrolimus concentration for myasthenia gravis treatment.
Kanai T; Uzawa A; Kawaguchi N; Himuro K; Oda F; Ozawa Y; Kuwabara S
Eur J Neurol; 2017 Feb; 24(2):270-275. PubMed ID: 28102047
[TBL] [Abstract][Full Text] [Related]
30. Recurrence of focal segmental glomerulosclerosis after renal transplantation: a case report.
Akash N
Saudi J Kidney Dis Transpl; 2007 Mar; 18(1):91-4. PubMed ID: 17237899
[TBL] [Abstract][Full Text] [Related]
31. Combination of immunosuppressive agents in treatment of steroid-resistant minimal change disease and primary focal segmental glomerulosclerosis.
El-Reshaid K; El-Reshaid W; Madda J
Ren Fail; 2005; 27(5):523-30. PubMed ID: 16152989
[TBL] [Abstract][Full Text] [Related]
32. Benefits of FK 506 for refractory eye symptoms in a young child with ocular myasthenia gravis.
Ishigaki K; Shishikura K; Murakami T; Suzuki H; Hirayama Y; Osawa M
Brain Dev; 2009 Sep; 31(8):634-7. PubMed ID: 18845408
[TBL] [Abstract][Full Text] [Related]
33. Effective treatment of a 13-year-old boy with steroid-dependent ocular myasthenia gravis using tacrolimus.
Mori T; Mori K; Suzue M; Ito H; Kagami S
Brain Dev; 2013 May; 35(5):445-8. PubMed ID: 22840813
[TBL] [Abstract][Full Text] [Related]
34. Treatment of FSGS in Children.
Sethna CB; Gipson DS
Adv Chronic Kidney Dis; 2014 Mar; 21(2):194-9. PubMed ID: 24602468
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of tacrolimus for myasthenia gravis: a systematic review and meta-analysis.
Wang L; Zhang S; Xi J; Li W; Zhou L; Lu J; Lu J; Zhang T; Zhao C
J Neurol; 2017 Nov; 264(11):2191-2200. PubMed ID: 28921038
[TBL] [Abstract][Full Text] [Related]
36. Clinical efficacy and immunological impact of tacrolimus in Chinese patients with generalized myasthenia gravis.
Zhao CB; Zhang X; Zhang H; Hu XQ; Lu JH; Lu CZ; Xiao BG
Int Immunopharmacol; 2011 Apr; 11(4):519-24. PubMed ID: 21195813
[TBL] [Abstract][Full Text] [Related]
37. Ocular myasthenia gravis patients following the administration of tacrolimus and steroids.
Omata T; Fukui K; Kodama K; Watanabe Y; Aoyama H; Fujii K; Shimojo N
J Neurol Sci; 2019 Jan; 396():30-32. PubMed ID: 30399462
[No Abstract] [Full Text] [Related]
38. Benefits of FK506 (tacrolimus) for residual, cyclosporin- and prednisone-resistant myasthenia gravis: one-year follow-up of an open-label study.
Ponseti JM; Azem J; Fort JM; Codina A; Montoro JB; Armengol M
Clin Neurol Neurosurg; 2005 Apr; 107(3):187-90. PubMed ID: 15823673
[TBL] [Abstract][Full Text] [Related]
39. Tacrolimus for myasthenia gravis: a clinical study of 212 patients.
Ponseti JM; Gamez J; Azem J; López-Cano M; Vilallonga R; Armengol M
Ann N Y Acad Sci; 2008; 1132():254-63. PubMed ID: 18096852
[TBL] [Abstract][Full Text] [Related]
40. [Successful treatment by tacrolimus in two patients with Osserman's grade III intractable myasthenia gravis and elderly IIb].
Iwamoto T; Ioka M; Naito Y; Kagawa Y; Kuzuhara S; Kojima M
Yakugaku Zasshi; 2004 Apr; 124(4):237-41. PubMed ID: 15067188
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
